以岭药业(002603) - 2024 Q2 - 季度业绩预告

Financial Performance Expectations - The company expects a net profit of between 433.63 million yuan and 642.41 million yuan for the first half of 2024[3] - Net profit attributable to shareholders is projected to decline by 60% to 73% compared to the same period last year, which reported a profit of 1,606.02 million yuan[3] - The net profit after deducting non-recurring gains and losses is estimated to be between 415.96 million yuan and 616.24 million yuan, also reflecting a decline of 60% to 73% year-on-year[3] - Basic earnings per share are expected to be between 0.26 yuan and 0.38 yuan, down from 0.96 yuan per share in the same period last year[3] Reasons for Performance Decline - The decline in performance is primarily attributed to decreased market demand for respiratory products due to high inventory levels and last year's high base effect[4] Financial Data and Auditing - The earnings forecast has not been audited by the accounting firm, but preliminary discussions indicate no discrepancies[4] - The financial data provided is based on preliminary calculations by the company's finance department and will be finalized in the 2024 semi-annual report[5] Investment Advisory - Investors are advised to make cautious decisions and be aware of investment risks[6]